Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 359-364

  Sanlioglu, Ahter Dilsad ^a   Koksal, Ismail Turker ^a   Ciftcioglu, Akif ^a   Baykara, Mehmet ^a   Luleci, Guven ^a   Sanlioglu, Salih ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

apoptosis; gene therapy; prostate; prostatic neoplasms; TNF related apoptosis inducing ligand

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; PARAFFIN; RECEPTOR SUBUNIT; TRAIL RECEPTOR 4; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADVANCED CANCER; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33845332700     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.087     Document Type: Article

References (20)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8
2. Hsieh C.L., and Chung L.W. New perspectives of prostate cancer gene therapy: molecular targets and animal models. Crit Rev Eukaryot Gene Expr 11 (2001) 77
3. Sanlioglu A.D., Koksal T., Baykara M., Luleci G., Karacay B., and Sanlioglu S. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Gene Ther Mol Biol 7 (2003) 113
4. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 (2001) 2603
5. Nagane M., Huang H.J., and Cavenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis 6 (2001) 191
6. Griffith T.S., and Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10 (1998) 559
7. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276 (2001) 10767
8. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818
9. French L.E., and Tschopp J. The TRAIL to selective tumor death. Nat Med 5 (1999) 146
10. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161 (1998) 2833
11. Kagawa S., He C., Gu J., Koch P., Rha S.J., Roth J.A., et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61 (2001) 3330
12. Frese S., Brunner T., Gugger M., Uduehi A., and Schmid R.A. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123 (2002) 168
13. Sanlioglu A.D., Koksal I.T., Karacay B., Baykara M., Luleci G., and Sanlioglu S. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 13 (2006) 21
14. Sanlioglu A.D., Dirice E., Aydin C., Erin N., Koksoy S., and Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5 (2005) 54
15. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumors. 6th ed. (2002), Wiley-Liss, New York
16. Koksal I.T., Ozcan F., Kilicaslan I., and Tefekli A. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features. Pathology 34 (2002) 233
17. Shankar S., Chen X., and Srivastava R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62 (2005) 165
18. Sridhar S., Ali A.A., Liang Y., El Etreby M.F., Lewis R.W., and Kumar M.V. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res 61 (2001) 7179
19. Shankar S., Singh T.R., and Srivastava R.K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61 (2004) 35
20. Sanlioglu A.D., Aydin C., Bozcuk H., Terzioglu E., and Sanlioglu S. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer 44 (2004) 199